Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc

NEW YORK, Jan. 2, 2018 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), concerning the proposed acquisition of Sucampo by Mallinckrodt plc (NYSE: MNK).  Under the terms of the proposed acquisition, Sucampo's shareholders will receive $18.00 per share in cash through a tender offer, for a total transaction value of $1.2 billion.  According to one analyst, Sucampo's Phase 2 and 3 assets are worth $29 per share on their own.

Wolf Popper is investigating claims on behalf of investors in Sucampo concerning the transaction.  Sucampo's shareholders seeking more information about the transaction or Wolf Popper's investigation can contact Mr. Stine at (212) 759-4600 or cstine@wolfpopper.com.

Wolf Popper has extensive experience representing investors in mergers and acquisition lawsuits and has successfully ensured that investors receive the maximum compensation.  Twelve Wolf Popper attorneys were named Super Lawyers or Rising Stars in the 2017 Super Lawyers New York City Metro Edition, including Wolf Popper partner Carl Stine, who was included in the Super Lawyers Top 100 List for the New York City Metro area.  View Wolf Popper attorney biographies at www.wolfpopper.com.

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

Wolf Popper LLP
845 Third Avenue
New York, New York 10022
Telephone: 212-759-4600
Toll Free Tel: 877-370-7703
Toll Free Fax: 877-370-7704
Email: cstine@wolfpopper.com

View original content:http://www.prnewswire.com/news-releases/wolf-popper-llp-investigates-the-proposed-acquisition-of-sucampo-pharmaceuticals-inc-by-mallinckrodt-plc-300576437.html

SOURCE Wolf Popper LLP